within Pharmacolibrary.Drugs.ATC.N;

model N05AL05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.48,
    Cl             = 6.5e-06,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0064,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 900,            
    Vdp             = 0.0173,
    k12             = 0.56,
    k21             = 0.56
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AL05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Amisulpride is an atypical antipsychotic medication primarily used to treat schizophrenia and, in some countries, depressive disorders. It acts mainly as a selective dopamine D2 and D3 receptor antagonist. Amisulpride is approved and marketed in several countries, but not in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics observed in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Sutar, R, et al., &amp; Chaudhary, P (2021). Antipsychotics and hemodialysis: A systematic review. <i>Asian journal of psychiatry</i> 55 102484–None. DOI:<a href=\"https://doi.org/10.1016/j.ajp.2020.102484\">10.1016/j.ajp.2020.102484</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33341539/\">https://pubmed.ncbi.nlm.nih.gov/33341539</a></p></li><li><p>B, PJ, et al., &amp; Dubey, B (2019). Oral Bioavailability Enhancement of Amisulpride: Complexation and its Pharmacokinetics and Pharmacodynamics Evaluations. <i>Drug metabolism letters</i> 13(2) 132–144. DOI:<a href=\"https://doi.org/10.2174/1872312813666191018152226\">10.2174/1872312813666191018152226</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31975684/\">https://pubmed.ncbi.nlm.nih.gov/31975684</a></p></li><li><p>Hamon-Vilcot, B, et al., &amp; Piette, F (1998). Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. <i>European journal of clinical pharmacology</i> 54(5) 405–409. DOI:<a href=\"https://doi.org/10.1007/s002280050483\">10.1007/s002280050483</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9754984/\">https://pubmed.ncbi.nlm.nih.gov/9754984</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AL05;
